A new study published in The Journal of Pain (May 2026) shows that cannabidiol (CBD) may have selective opioid-sparing effects. Researchers at the University of Florida conducted an animal study examining whether orally administered CBD could reduce the opioid dose required for pain relief — a finding that could prove significant in light of the ongoing opioid crisis.
Opioid crisis drives need for alternative pain treatments
The opioid crisis has been one of the most serious public health challenges in the United States and many other countries over the past decades. The need for alternative or complementary pain relief strategies is therefore substantial. Cannabidiol, the non-psychoactive cannabinoid from the cannabis plant, has shown potential as a pain-relieving agent in previous studies. However, many of these studies have used routes of administration such as subcutaneous or intraperitoneal injections — methods that do not correspond to how humans actually use CBD in clinical practice, namely orally.
The study was conducted by researchers at the University of Florida College of Dentistry in collaboration with departments of neuroscience, psychiatry, and pharmacy.
Get the week’s important news from Cannabis.se in your inbox — interesting weekend reading! 🥦✉️
CBD enhanced opioid pain relief in animal model
The study, titled “Selective opioid-sparing effects of cannabidiol on opioid analgesia in rats”, demonstrates that CBD has selective opioid-sparing effects. This means that CBD specifically enhances the pain-relieving properties of opioids rather than having a general analgesic effect. This is an important distinction because it suggests that the combination of CBD and opioid may be more effective than higher doses of opioid alone — and could thereby reduce the risk of opioid-related side effects such as respiratory depression, tolerance, and dependence.
In a previous study by the same research group (Brice-Tutt et al., 2025, Pharmacology, Biochemistry, and Behavior), the method of oral administration was established. Rats (both male and female) received oral CBD (25 mg/kg) together with oxycodone (1.4 mg/kg) and were tested in an operant thermal pain model where the animals voluntarily exposed their faces to heat to obtain a reward. The results showed that the combination provided significantly better pain relief than oxycodone alone.
Animal study warrants caution when interpreting results
Since the study was conducted on rats, the results cannot be directly translated to humans. Clinical trials are needed before CBD can be recommended as a standard component of pain management. The researchers themselves emphasize that their results “encourage the notion that cannabidiol could find utility as an opioid-sparing approach to treating pain,” but that more research is required.
What does the study mean for medical cannabis?
The research strengthens the case for CBD as a potential opioid-sparing treatment. The fact that the study uses oral administration — the same route humans use — makes the results more transferable to clinical practice than previous injection-based animal studies. The study was funded by the NIH/National Institute on Drug Abuse (grant R01DA049470) and published in the scientific journal The Journal of Pain.
Source
Selective opioid-sparing effects of cannabidiol on opioid analgesia in rats
Sponsor: Sensi Seeds are one of Europe’s most recognized names in premium cannabis genetics, offering a wide selection of feminized, autoflowering, CBD-rich and F1 hybrid seeds for customers who want quality, consistency and choice.